Centre for Chronic Immunodeficiencies, Freiburg, Germany.
Clin Exp Immunol. 2014 Dec;178 Suppl 1(Suppl 1):162. doi: 10.1111/cei.12554.
The pan-European survey provides useful information on the accessibility and trends of intravenous and subcutaneous immunoglobulin (IVIg/SCIg) therapy, which is used to treat primary immunodeficiency disorders (PIDs). Although immunoglobulin (Ig) therapy is the first-line treatment for PIDs, the mechanisms of action of Ig therapy may differ according to the condition it is used to treat. Moreover, intriguing presentations suggest that further investigation is required to understand more clearly both the haematological and immunoregulatory effects of therapeutic immunoglobulin. This can ultimately provide more information on optimizing Ig therapy efficacy, and establish whether individualized dosing regimens for patients will be conducive to better clinical outcomes. In addition to treating autoimmune and inflammatory conditions, there is evidence to suggest that immunoglobulins can potentially play a role in transplantation, which warrants further investigation for future use.
这项泛欧调查提供了有关静脉内和皮下免疫球蛋白 (IVIg/SCIg) 治疗的可及性和趋势的有用信息，该治疗用于治疗原发性免疫缺陷疾病 (PID)。尽管免疫球蛋白 (Ig) 治疗是 PID 的一线治疗方法，但 Ig 治疗的作用机制可能因所治疗的疾病而异。此外，有趣的临床表现表明，需要进一步研究以更清楚地了解治疗性免疫球蛋白的血液学和免疫调节作用。这最终可以提供更多关于优化 Ig 治疗效果的信息，并确定为患者制定个体化剂量方案是否有利于更好的临床结果。除了治疗自身免疫和炎症性疾病外，有证据表明免疫球蛋白可能在移植中发挥作用，这值得进一步研究，以备将来使用。
